Anzeige
Mehr »
Sonntag, 07.09.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QMUH | ISIN: US92790C1045 | Ticker-Symbol: 1S1
Tradegate
05.09.25 | 14:14
15,620 Euro
-2,25 % -0,360
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIRIDIAN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIRIDIAN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
15,85017,09505.09.
15,82016,14005.09.

Aktuelle News zur VIRIDIAN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.08.These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results2
06.08.Viridian Therapeutics, Inc.\DE - S-8, Securities to be offered to employees in employee benefit plans1
06.08.Viridian Therapeutics, Inc.\DE - 10-Q, Quarterly Report-
06.08.Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
06.08.Viridian Therapeutics GAAP EPS of -$1.00 beats by $0.03, revenue of $0.08M beats by $0.03M2
31.07.Viridian and Kissei to advance veligrotug and VRDN-003 in Japan2
30.07.Viridian partners with Japanese firm for Veligrotug and VRDN-0031
30.07.Viridian Therapeutics, Inc.\DE - 8-K, Current Report4
VIRIDIAN THERAPEUTICS Aktie jetzt für 0€ handeln
20.05.Viridian Therapeutics, Inc.\DE - 8-K, Current Report5
08.05.What 5 Analyst Ratings Have To Say About Viridian Therapeutics8
06.05.Stifel maintains Buy on Viridian Therapeutics, $41 target6
06.05.Viridian Therapeutics, Inc.\DE - 10-Q, Quarterly Report2
06.05.Viridian Therapeutics GAAP EPS of -$0.87 beats by $0.11, revenue of $0.07M beats by $0.03M1
06.05.Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
07.04.Viridian Therapeutics appoints Jeff Ajer to board2
07.04.Viridian Therapeutics, Inc.\DE - 8-K, Current Report1
04.04.Stifel maintains Buy on Viridian Therapeutics, $41 target3
11.03.Viridian Therapeutics Announces Inducement Stock Option Grants1
12.11.24Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data277WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1